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Abstract  
Type 2 diabetes (T2D) and Alzheimer’s disease (AD) are two progressive disorders with high 
prevalence worldwide. Polymorphisms in tumor necrosis factor-alpha (TNF-α) and 
apolipoprotein E (ApoE) genes might be associated with both T2D and AD, representing 
possible genetic markers for the development of the AD in subjects with T2D. The aim was to 
determine ApoE and G-308A TNF-α gene polymorphisms in unrelated Croatian Caucasians: 
207 patients with sporadic AD, 196 T2D patients and 456 healthy controls. Patients with AD 
had higher frequency of ApoE4 allele compared to T2D patients and controls. The significant 
association, observed between ApoE2 allele and T2D, disappeared after the data were 
adjusted for age and sex. The genotype or allele frequencies of G-308A TNF-α gene 
polymorphism were similar among the patients with AD, T2D and healthy controls. In 
conclusion, these results do not support the hypothesis that the A allele of G-308A TNF-α 
gene polymorphism is associated either with AD or T2D. Our data confirm the association 
between the ApoE4 allele and AD, and point out the E2 allele of ApoE gene as the possible 
risk factor for T2D.   
 
 
Key words: Alzheimer’s disease; apolipoprotein E; diabetes type 2; gene; polymorphism; 
tumor necrosis factor- alpha  
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Introduction 
 
Type 2 or non-insulin-dependent diabetes (T2D) and Alzheimer’s disease (AD) are two 
progressive, disability-inducing disorders with high prevalence across the world. Although 
these diseases have different aetiology and pathophysiology, such as characteristic 
degeneration of pancreatic beta cells and/or insulin resistance in T2D (ADA 2011) and 
progressive atrophy of neocortical/limbic brain areas in AD (Perl 2010), the high incidence of 
AD was observed in T2D patients (Irie et al. 2008) and inversely T2D in patients with AD 
(Janson et al. 2004).  
The common underlying biochemical and genetic dysfunctions in these disorders are 
unclear (Zhao and Townsend 2009). The findings of two main neuropathological hallmarks of 
AD, beta-amyloid (Aβ) plaques and neurofibrillary tangles (Perl 2010) in pancreas of T2D 
patients (Miklossy et al. 2010), and involvement of ApoE protein in both disorders, suggest s 
common underlying mechanisms. The glycoprotein apolipoprotein E (ApoE), with its three 
isoforms E2, E3 and E4 (Achaya et al. 2002), plays an important role in the lipid metabolism, 
and transport of cholesterol and phospholipids (Schipper 2011). The role of ApoE4 isoform in 
the formation of Aβ plaques and its importance as a risk factor for development of AD, have 
been often discussed (Messier 2003; Kim et al. 2009; Schipper 2011). Since insulin resistance 
is known to be associated with metabolic dyslipidemia (Sijbrands et al. 1994), ApoE isoforms 
with their functions in lipid metabolism could also play an important role in pathogenesis of 
T2D (Anthopoulos et al. 2010).   
Other plausible common pathogenic component in both AD and T2D is inflammation 
(Bierhaus and Nawroth 2009). It has been shown that hyperinsulinemia, induced by peripheral 
insulin administration, elevated cerebrospinal fluid (CSF) levels of tumor necrosis factor-
alpha (TNF-α), IL-1α, IL-1β and IL-6, and stimulated amyloidogenesis in healthy volunteers 
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(Fishel et al. 2005). TNF-α is a pro-inflammatory cytokine that regulates inflammatory and 
immune responses. It has an important role in the pathophysiology of several disorders, such 
as coronary heart disease (Vendrell et al. 2003), obesity (Dandona et al. 1998) and AD (Di 
Bona et al. 2009). The transcription and secretion of TNF-α are regulated by the promoter G-
308A polymorphism of the TNF-α gene, with –308A allele related to high TNF–α values 
(Wilson et al. 1997). 
Since there is a lack of data on the association between ApoE and TNF-α genetic 
variants and their correlation with T2D and AD, the aim of the study was to determine the 
genotype and allele frequencies of G-308A TNF-α promoter polymorphism and ApoE gene 
polymorphism in AD and T2D patients and healthy control subjects. The hypothesis was that 
patients with T2D and AD have higher frequency of the TNF-α rare -308A allele and the 
ApoE4 allele than healthy controls. 
 
Methods  
 
Study population  
 
This study included 859 unrelated Croatian Caucasian subjects:  207 patients (mean age ± SD, 
80.3 ± 7.1 years; 132 female) with AD hospitalized at University Psychiatric Hospital, 
Vrapce, 196 patients (64.8 ± 9.3 years; 56 female) with T2D treated in Vuk Vrhovac 
University Clinic in Zagreb, the WHO collaborating center for diabetes in Croatia (Alberti et 
al. 1998) and 456 healthy older volunteers (77.4 ± 5.4 years; 186 female) participants in the 
longitudinal epidemiological study at Institute for Medical Research and Occupational Health 
in Zagreb. The probable AD was diagnosed according to the criteria of the National Institute 
of Neurologic and Communicative Disorders and Stroke and the Alzheimer‘s Disease and 
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Related Disorders Association (NINDS-ADRDA) (McKhann et al. 1984) and Diagnostic and 
Statistical Manual of Mental Disorders Fourth Edition (DSM-IV, APA 1994). Patients with 
vascular dementia were excluded. Patients with diabetes were carefully assessed and 
diagnosed as type 2 according to the recommendations of the World Health Organization 
(WHO) and Standards of Medical Care in Diabetes from the American Diabetes Association 
(ADA 2011). The cognitive status was evaluated by Mini Mental State Examination (MMSE) 
(Folstein et al. 1975), translated and validated for Croatian population (www.parinc.com). 
MMSE score in controls and patients with T2D was in normal range (26-30), while the range 
in patients with AD was 0-20.  
All participants underwent a clinical interview for evaluation of current and past 
medical status. Exclusion criteria for all participants were diagnoses of severe somatic 
diseases and major psychiatric disorders. Patients with AD were treated with 
acetylcholinesterase inhibitors. Oral hypoglycaemic drugs and insulin were used in 54 and 
141 T2D patients, respectively.  
The study was approved by the local Ethics Committees and was in agreement with 
the ethical standards laid down in the 1964 Declaration of Helsinki. Informed consent was 
obtained from participants or in the case of AD from their guardians. 
 
Blood collection and DNA extraction  
 
Venous blood samples (4 ml) were drawn from all subjects into plastic syringe with 1 ml of acid 
citrate dextrose anticoagulant.  Genomic DNA was extracted from whole blood samples using 
salting out procedure (Miller et al. 1988). Genotyping of TNF-α (rs1800896) and ApoE 
(rs7412 and rs429358) was performed on ABI Prism 7000 Sequencing Detection System 
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(ABI) using a Taqman SNP genotyping assays in conditions recommended by Applied 
Biosystems (Foster City, CA, USA).  
 
 
 
Statistical analysis 
 
The genotype and allele distributions and deviations from Hardy - Weinberg equilibrium were 
determined by a χ
2
-test. The univariate and multiple (adjusted for age and sex) logistic 
regression were implemented for testing the association of AD or T2D with of TNF-α and 
ApoE polymorphisms. Differences in age and glucose levels between groups were assessed 
by Kruskal-Wallis one way analysis of variance on ranks followed by Mann-Whitney test for 
between groups comparison. The statistical packages used were GraphPad Prism and Sigma 
Stat 3.5 (Jandell Scientific Corp. San Raphael, California, USA). The level of significance 
was set to α = 0.05, with 2-tailed p values. 
 
Results  
 
As expected, glucose levels differed significantly (H=101.01; df=2; p <0.001, Kruskal-Wallis 
ANOVA) among groups, with the highest values in T2D patients (8.7 ± 3.1 mmol/l; mean ± 
SD) compared to AD patients (6.4 ± 8.0 mmol/l) and healthy controls (6.4 ± 2.4 mmol/l). 
Significant (H=286.97; df = 2; p < 0.001) age difference was observed among groups. Patients 
with AD were significantly (p<0.05) older than controls and patients with T2D, while controls 
were older than T2D patients.  No significant deviation from the Hardy-Weinberg equilibrium 
was found in G-308A TNF-α genotypes for patients with AD (χ2 = 0.45; df = 1; p= 0.505), 
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patients with T2D (χ2 = 0.90; df = 1; p = 0.343) and healthy control subjects (χ2 = 0.857; df = 
1; p = 0.354). The distribution of the ApoE polymorphism genotypes (rs7412 and rs429358) 
did not deviate from the Hardy-Weinberg equilibrium in AD patients (χ2 = 4.52; df = 1; p = 
0.211), T2D patients (χ2 = 3.27; df = 1; p = 0.353) and healthy subjects (χ2 = 4.60; df = 1; p = 
0.204). 
Significant differences in the frequencies of ApoE genotypes, alleles and E2 or E4 
carriers were observed among controls and AD or T2D patients (Table 1). Between groups 
comparison showed significant differences in genotype (χ2 =18.16, df = 5, p = 0.003) or allele 
(χ2 = 8.82, df = 2, p = 0.012) frequencies of the ApoE polymorphism (Table 1) between AD 
patients and controls. AD patients also differed from T2D patients in ApoE genotype (χ2 
=14.35, df = 5, p = 0.014) and allele (χ2 = 6.66, df = 2, p = 0.036) frequencies. There was 
significant (χ2 = 6.22, df = 2, p = 0.047) difference in the ApoE allele, but not in the genotype 
(χ2 =10.04, df = 5, p = 0.074) frequencies between T2D patients and controls. The comparison 
of ApoE2 carriers and non-carriers between groups revealed significantly (χ2 = 6.31, df = 1, p 
= 0.012) more ApoE2 carriers among T2D patients than in controls and comparable 
distribution of ApoE2 carriers in AD and T2D patients (χ2 = 3.61, df = 1, p = 0.057), or in AD 
patients and controls (χ2 = 0.000, df = 1, p = 0.982). The assessment of ApoE4 carriers and 
non-carriers between groups revealed more ApoE4 carriers among AD patients when 
compared to controls (χ2 = 6.28, df = 1, p = 0.012) or to T2D patients (χ2 = 4.01, df = 1, p = 
0.045), but similar frequency of ApoE4 carriers in controls and T2D patients (χ2 = 0.01, df = 
1, p = 0.915).  
The G-308A TNF-α polymorphism genotype, or allele frequencies did not differ 
significantly between or within the studied groups (Table 2). No significant differences were 
detected in the genotype frequencies between AD (χ2 = 2.188, df = 2, p = 0.335) or T2D (χ2 = 
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1.975, df = 2, p = 0.373) patients when compared to healthy controls or AD and T2D patients 
(χ2 = 2.188, df = 2, p = 0.335). Allele frequencies between controls and AD (χ2 = 1.186, df = 
1, p = 0.276) or T2D subjects (χ2 = 0.178, df = 1, p = 0.673), or between AD and T2D patients 
(χ2 = 1.775, df = 1, p = 0.183) showed no significance. The frequency of A allele carriers 
(Table 2) was similar between healthy subjects and AD patients (χ2 = 0.580, df = 1, p = 0.446) 
or T2D patients (χ2 = 0.585, df = 1, p = 0.444), or between AD and T2D patients (χ2 = 1.812, 
df = 1, p = 0.178). 
Potential risk factors for AD and T2D were tested separately using univariate logistic 
regression model. It revealed a significant (p <0.0001) effect of sex and age in T2D and AD. 
The multivariate logistic regression model was used to predict association of -308A allele of 
TNF-α gene with T2D, with data adjusted for well known risk factors to exclude their 
confounding effect (Table 3). While univariate model showed a significant (p = 0.009) 
association of ApoE2 allele with T2D, statistical significance was lost in the multivariate 
logistic regression model when adjusted for age, sex and TNF-α. Both univariate (p = 0.010) 
and multivariate (p = 0.001) analyses (adjusted for age, sex and TNF- α) have shown that 
ApoE4 significantly predicted a risk for AD, but not for T2D. In both models allele -308A 
TNF-α showed no association with T2D or AD when data were adjusted for age, sex and 
presence of ApoE2 or ApoE4 allele (Table 3).  
 
Discussion 
 
            Our results confirmed the previously described association of E4 allele and AD, 
(Farrer et al. 1997) supporting the ApoE gene variant as a risk factor for the development of 
AD (Leduc et al. 2010). ApoE4 allele might play an important role in the pathophysiology of 
AD (Leduc et al. 2010; Perl 2010). The E4 carriers exhibit reduced clearance with 
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consequently higher deposition of toxic Aβ, enhanced formation of neurofibrillary tangles,  
and insufficient neuronal damage repair, compared to E2 and E3 carriers (Perl 2010).  
The relationship between ApoE gene variants and T2D is unclear. The ethnic 
differences in the frequency of ApoE alleles have been described, such as the higher 
frequency of E4 allele in Caucasians than Chinese (Burman et al. 2009).  However, our data 
showed no difference in ApoE allele frequencies in Croatian compared to Chinese T2D 
patients (Ma et al. 2008). In addition, our hypothesis that T2D patients, like AD patients, have 
higher frequency of ApoE4 allele compared to healthy controls, has not been confirmed. The 
reason could be a difference in patients’ age. In the association meta-analysis between ApoE 
alleles and age in healthy population (Farrer et al. 1997), the frequencies of E2 and E3 alleles 
increased, while the frequency of E4 allele decreased with aging. Nevertheless, we cannot 
exclude the possibility that younger E4 carriers among T2D patients might develop AD later 
in life.  Since T2D ApoE4 allele carriers are at higher risk for the earlier occurrence of 
cognitive decline and dementia compared to E2 or E3 allele carriers (Irie et al. 2008), a 
longitudinal follow-up study would be necessary to evaluate the association between E4 allele 
and incidence of AD in our population of T2D patients.  
Previous studies of AD and T2D were focused primarily on the frequency of E4 allele, 
providing insufficient data about the other ApoE variants. In agreement with the literature 
(Farrer et al. 1997), we found that E3 allele was the most common ApoE allele in healthy 
subjects, as well as in AD and T2D patients. In addition, a higher frequency of the rare E2 
allele carriers in T2D patients compared to controls and AD patients, was also found. 
However, logistic regression analysis suggested that the observed association between the E2 
variant and T2D was related to sex and age differences. To our knowledge, there is only one 
study (Errera et al. 2006) that reported a higher frequency of E2 allele in the small number of 
male and female diabetic patients (type 1 and type 2) of African-Brazilian and European-
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Brazilian origins (Errera et al. 2006). Unfortunately, this study (Errera et al. 2006) did not 
evaluate the effects of sex and age in order to confirm the association between E2 allele and 
diabetes. Although E2 might be protective against the development of AD (Farrer et al. 1997), 
it could be detrimental for T2D. The role of ApoE gene variants, especially E2, in T2D is 
unknown. E2 might be related to altered lipid metabolism in T2D (Dallongeville et al. 1991). 
Since E2 variant has a low affinity for the low density lipoprotein cholesterol (LDL-C) 
receptors (Brown and Goldstein 1983) and induces their up-regulation in liver (Brown and 
Goldstein 1983), it could be associated with altered plasma cholesterol levels (Schiele et al. 
2000), high triglyceride levels (Dallongeville et al. 1991), high ApoE levels (Schiele et al. 
2000), insulin resistance, hyperlipidemia (Dallongeville et al. 1991) and obesity (Dandona et 
al. 1998).  It has also been shown that ApoE2 allele carriers have different composition of 
LDL-C levels, including very dense intermediate-density proteins, compared to the other 
genotypes (Murdoch et al. 2007). 
Our results show that allele frequencies of the G-308A TNF-α polymorphism in 
Croatian control subjects are in line with the frequencies observed in other healthy 
populations (Vendrell et al. 2003). The distribution of genotypes and alleles of the G-308A 
TNF-α polymorphism observed in our AD patients is in accordance with the recent meta-
analysis (Di Bona et al. 2009) showing no association of TNF-α gene variants with the 
occurrence of AD.  
The studies about the association between G-308A TNF-α gene polymorphism and 
T2D presented inconsistent results (Hamann et al. 1995; Koch et al. 2000; Kubaszek et al. 
2003). We found no association between TNF-α gene variants and T2D, which is in 
agreement with the previous data showing a lack of increased risk for A allele carriers to 
develop T2D compared to G allele carriers (Hamann et al. 1995), and a lack of association 
between TNF-α gene variants and insulin sensitivity or secretion in the first-degree relatives 
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of T2D patients (Koch et al. 2000). In contrast, other studies (Kubaszek et al. 2003) reported a 
correlation between A allele and development of T2D, probably due to the higher 
transcriptional activity and increased TNF-α production in A allele carriers.  
Several limitations of our study should be mentioned. Taking into account aging as a 
risk factor for AD, the possibility that our T2D patients might develop AD in older age could 
not be excluded, since they were younger than AD patients and healthy controls. Although 
only 9% of T2D patients were E4 carriers, a longitudinal follow-up study would be necessary 
to confirm E4 allele as a risk factor for the occurrence of AD in T2D patients. Moreover, we 
did not determine plasma lipid levels and prevalence of coronary heart disease in control 
subjects, AD and T2D patients due to the technical reasons. The advantages of the present 
study were well-defined groups of unrelated Caucasians exposed to similar environmental and 
lifestyle factors.   
 
Conclusions  
 
The E2 allele of the ApoE gene might be the risk factor for T2D. An association between the 
E4 allele and AD, but not T2D was found. The genotype or allele frequencies of G-308A 
TNF-α gene polymorphism were similar between patients with AD, T2D and healthy controls.  
The hypothesis that AD and T2D patients have similar distribution of the TNF-α gene and the 
ApoE gene variants was not confirmed. 
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Table 1. Genotype, allele and E4 carrier count (N) and frequencies (%) of ApoE gene 
polymorphism (rs7412 and rs429358) in healthy controls, patients with type 2 diabetes (T2D) 
and patients with Alzheimer’s disease (AD). 
 
 Healthy controls T2D AD 
 (456) (196) (207) 
Genotype N (%) N (%) N (%) 
E2/2 1 (0.2) 0 (0.0) 2 (1.0) 
E2/3 48 (10.5) 35 (17.9) 16 (7.7) 
E2/4 2 (0.5) 2 (1.0) 6 (2.9) 
E3/3 328 (71.9) 127 (64.8) 135 (65.2) 
E3/4 76 (16.7) 30 (15.3) 44 (21.3) 
E4/4 1 (0.2) 2 (1.0) 4 (1.9) 
 χ
2
=29.55, df=10, p=0.001 
Alele    
E2 52 (5.7) 37 (9.4) 26 (6.3) 
E3 780 (85.5) 319 (81.4) 330 (79.7) 
E4 80 (8.8) 36 (9.2) 58 (14.0) 
 χ2=15.38, df=4, p=0.004 
Carriers    
E2 carriers 51 (11.2) 37 (18.8) 24  (11.6) 
 18
E2 non carriers 405 (88.8) 159 (81.2) 183 (88.4) 
 χ2=7.65, df=2, p=0.022 
E4 carriers 79 (17.3) 34  (17.4) 54  (26.1) 
E4 non carriers 377 (82.7) 162 (82.6) 153 (73.9) 
 χ2=7.69, df=2, p=0.021 
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Table 2. Genotype, allele and carriers (GG vs. AA+AG) count (N) and frequencies (%) of G-
308A TNF-α gene polymorphism in healthy controls, patients with type 2 diabetes (T2D) and 
patients with Alzheimer’s disease (AD). 
 
  
Healthy controls 
(456) 
T2D 
(196) 
AD 
(207) 
Genotype N (%) N (%) N (%) 
AA 12 (2.6) 3 (1.5) 2 (1.0) 
AG 108 (23.7) 55 (28.1) 46 (22.2) 
GG 336 (73.7) 138 (70.4) 159 (76.8) 
 χ2=4.39, df=4, p=0.356 
Alele    
A 132 (14.5) 61 (15.6) 50 (12.1) 
G 
  
780 (85.5) 331 (84.4) 364 (87.9) 
χ2=2.19, df=2, p=0.335 
Carriers    
GG 336 (73.7) 138 (70.4) 159 (76.8) 
AA + AG 
  
120 (26.3) 58 (29.6) 48 (23.2) 
χ2=2.13, df=2, p=0.345 
 
 
 
 
 
 
2
0
T
a
b
le
 3
. 
 L
o
g
is
ti
c 
re
g
re
ss
io
n
 a
n
al
y
si
s 
in
 p
at
ie
n
ts
 w
it
h
 t
y
p
e 
2
 d
ia
b
et
es
 (
T
2
D
) 
an
d
 p
at
ie
n
ts
 w
it
h
 A
lz
h
ei
m
er
’s
 d
is
ea
se
 (
A
D
) 
co
m
p
ar
ed
 t
o
 h
ea
lt
h
y
 
co
n
tr
o
ls
. 
 
T
2
D
 
A
D
 
 
u
n
iv
a
ri
a
te
 m
o
d
el
 
u
n
iv
a
ri
a
te
 m
o
d
el
 
p
re
d
ic
to
r 
N
 
β
 
S
E
 β
 
p
 
O
R
 
C
I 
N
 
β
 
S
E
 β
 
p
 
O
R
 
C
I 
ag
e
 
6
3
0
 
-0
.2
5
 
0
.0
2
 
<
0
.0
0
0
1
 
0
.7
8
 
0
.7
4
5
 -
 0
.8
1
0
 
6
4
1
 
0
.0
8
 
0
.0
1
 
<
0
.0
0
0
1
 
1
.0
9
 
1
.0
5
5
 -
 1
.1
1
8
 
se
x
 
6
3
0
 
1
.2
9
 
0
.1
8
 
<
0
.0
0
0
1
 
3
.6
3
 
2
.5
2
7
 -
 5
.2
1
1
 
6
6
3
 
-1
.7
6
 
0
.2
4
 
<
0
.0
0
0
1
 
0
.1
7
 
0
.1
0
7
 -
 0
.2
7
9
 
-3
0
8
 T
N
F
α
 A
 a
ll
el
e 
ca
rr
ie
r 
6
5
2
 
0
.1
6
 
0
.1
9
 
0
.3
9
0
 
0
.8
5
 
0
.5
8
7
 -
 1
.2
3
1
 
6
6
3
 
-0
.1
7
 
0
.2
0
 
0
.3
9
1
 
0
.8
5
 
0
.5
7
6
 -
 1
.2
4
1
 
E
2
 c
ar
ri
er
 
6
5
2
 
0
.6
1
 
0
.2
4
 
0
.0
0
9
 
1
.8
5
 
1
.1
6
5
 -
 2
.9
3
1
 
6
6
3
 
0
.0
4
 
0
.2
6
 
0
.8
7
7
 
1
.0
4
 
0
.6
2
2
 -
 1
.7
4
4
 
E
4
 c
ar
ri
er
 
6
5
2
 
0
.0
0
 
0
.2
3
 
0
.9
9
5
 
1
.0
0
 
0
.6
4
4
 -
 1
.5
5
9
 
6
6
3
 
0
.5
2
 
0
.2
0
 
0
.0
1
0
 
1
.6
8
 
1
.1
3
6
 -
 2
.4
9
7
 
 
m
u
lt
iv
a
ri
a
te
 m
o
d
el
 
m
u
lt
iv
a
ri
a
te
 m
o
d
el
 
p
re
d
ic
to
r 
N
 
β
 
S
E
 β
 
p
 
O
R
 
C
I 
N
 
β
 
S
E
 β
 
p
 
O
R
 
C
I 
-3
0
8
 T
N
F
α
 A
 a
ll
el
e 
ca
rr
ie
r 
*
 
6
3
0
 
0
.1
8
 
0
.2
7
 
0
.4
9
1
 
1
.2
0
 
0
.7
1
2
 -
 2
.0
3
3
 
6
4
1
 
-0
.1
8
 
0
.2
1
 
0
.3
9
8
 
0
.8
4
 
0
.5
5
1
 -
 1
.2
6
7
 
-3
0
8
 T
N
F
α
 A
 a
ll
el
e 
ca
rr
ie
r 
#
 
6
3
0
 
0
.1
6
 
0
.2
7
 
0
.5
5
5
 
1
.1
7
 
0
.6
9
5
 -
 1
.9
6
8
 
6
4
1
 
-0
.1
7
 
0
.2
1
 
0
.4
3
8
 
0
.8
5
 
0
.5
5
6
 -
 1
.2
8
9
 
E
2
 c
ar
ri
er
 *
*
 
6
3
0
 
0
.6
5
 
0
.3
4
 
0
.0
6
1
 
1
.9
1
 
0
.9
7
2
 -
 3
.7
5
1
 
6
4
1
 
0
.0
8
 
0
.2
9
 
0
.7
8
3
 
1
.0
8
 
0
.6
1
4
 -
 1
.9
1
2
 
E
4
 c
ar
ri
er
 *
*
 
6
3
0
 
-0
.1
1
 
0
.3
2
 
0
.7
2
9
 
0
.9
0
 
0
.4
8
2
 -
 1
.6
6
6
 
6
4
1
 
0
.7
1
 
0
.2
2
 
0
.0
0
1
 
2
.0
4
 
1
.3
1
4
 -
 3
.1
5
2
 
 *
 a
d
ju
st
ed
 f
o
r 
ag
e,
 s
ex
 a
n
d
 A
p
o
E
2
; 
 #
 a
d
ju
st
ed
 f
o
r 
ag
e,
 s
ex
 a
n
d
 A
p
o
E
4
; 
 *
*
 a
d
ju
st
ed
 f
o
r 
ag
e,
 s
ex
 a
n
d
 T
N
F
α
 A
 a
ll
el
e 
   
